EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Brain Delivery of Antibody-Derived Biologicals for Alzheimer’s Disease: An Updated Narrative Review

Rachita K Sumbria iD, Ruben J Boado

Antibodies · 17.04.2026 · 15 (2) · 37

DOI: 10.3390/antib15020037 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antibodies, online erschienen am 17.04.2026. Verfasst von Rachita K Sumbria und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical and Pharmaceutical Sciences and Center for Targeted Drug Delivery (CTDD), School of Pharmacy, Chapman University, Irvine, CA…. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, National Institute of Aging of the National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibodies directed against β-amyloid (Aβ) have been developed for the treatment of Alzheimer’s disease (AD). However, the in vivo central efficacy is reduced by the poor penetration of antibodies across the blood–brain barrier (BBB). In addition, these antibodies have been associated with adverse effects like amyloid-related imaging abnormalities. Thus, the development of new antibody-based therapies for AD with improved transport across the BBB may improve efficacy and reduce adverse effects. Antibodies targeting the BBB transferrin receptor (TfR) are able to cross the BBB through receptor-mediated transcytosis, producing a global distribution throughout the brain. Along the same line, bispecific antibodies directed to both the BBB TfR and Aβ showed enhanced brain uptake and pharmacological effects with diminished adverse side effects in experimental animal models of AD and in clinical trials. A generation of brain-penetrating fusion proteins targeting the BBB-TfR has been shown to represent novel treatments for AD, and this includes erythropoietin, tumor necrosis factor alpha inhibitors, neprilysin, somatostatin, oligonucleotides, and an antibody activating TREM2. The aim of this article is to review the progress made in the delivery of antibody-derived biologicals to the brain for AD, targeting the BBB-TfR.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer’s diseasebispecific antibodiesblood–brain barrierdecoy receptorsneurotrophinsprotein-based therapyreceptor-mediated transcytosistransferrin receptor

Autor:innen und Institutionen

  • Department of Biomedical and Pharmaceutical Sciences and Center for Targeted Drug Delivery (CTDD), School of Pharmacy, Chapman University, Irvine, CA 92618, USA.
  • Department of Neurology, University of California, Irvine, CA 92697, USA.
  • Department of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA.

ORCID-Profile: Rachita K Sumbria

Förderung

  • NIA NIH HHS
  • National Institute of Aging of the National Institutes of Health

Zitieren

APA

Sumbria, R. K., & Boado, R. J. (2026). Brain Delivery of Antibody-Derived Biologicals for Alzheimer’s Disease: An Updated Narrative Review. Antibodies, 15(2), 37. https://doi.org/10.3390/antib15020037

Vancouver

Sumbria RK, Boado RJ. Brain Delivery of Antibody-Derived Biologicals for Alzheimer’s Disease: An Updated Narrative Review. Antibodies. 2026;15(2):37. doi:10.3390/antib15020037

BibTeX
@article{Sumbria2026,
  author = {Sumbria, Rachita K and Boado, Ruben J},
  title = {Brain Delivery of Antibody-Derived Biologicals for Alzheimer’s Disease: An Updated Narrative Review},
  journal = {Antibodies},
  year = {2026},
  volume = {15},
  number = {2},
  pages = {37},
  doi = {10.3390/antib15020037}
}
Kostenlos starten →